129 related articles for article (PubMed ID: 22036141)
21. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
22. [Treatment of circumscribed choroidal haemangiomas by photodynamic therapy: a review].
Gambrelle J; Graswill C; Mauget-Faysse M; Kodjikian L; Cochener B; Grange JD
J Fr Ophtalmol; 2010 Sep; 33(7):497-504. PubMed ID: 20674083
[TBL] [Abstract][Full Text] [Related]
23. Photodynamic therapy with verteporfin for symptomatic circumscribed choroidal hemangioma: five-year outcomes.
Blasi MA; Tiberti AC; Scupola A; Balestrazzi A; Colangelo E; Valente P; Balestrazzi E
Ophthalmology; 2010 Aug; 117(8):1630-7. PubMed ID: 20417564
[TBL] [Abstract][Full Text] [Related]
24. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy.
Lai TY; Chan WM; Liu DT; Luk FO; Lam DS
Br J Ophthalmol; 2008 May; 92(5):661-6. PubMed ID: 18356265
[TBL] [Abstract][Full Text] [Related]
25. Effect of photodynamic therapy alone or combined with posterior subtenon triamcinolone acetonide or intravitreal bevacizumab on choroidal hypofluorescence by indocyanine green angiography.
Hatta Y; Ishikawa K; Nishihara H; Ozawa S; Ito Y; Terasaki H
Retina; 2010 Mar; 30(3):495-502. PubMed ID: 19996828
[TBL] [Abstract][Full Text] [Related]
26. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.
Lazic R; Gabric N
Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776
[TBL] [Abstract][Full Text] [Related]
27. Intravitreal ranibizumab and bevacizumab in combination with full-fluence verteporfin therapy and dexamethasone for exudative age-related macular degeneration.
Forte R; Bonavolontà P; Benayoun Y; Adenis JP; Robert PY
Ophthalmic Res; 2011; 45(3):129-34. PubMed ID: 20847575
[TBL] [Abstract][Full Text] [Related]
28. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238
[TBL] [Abstract][Full Text] [Related]
29. Retinal detachment with macular hole following combined photodynamic therapy and intravitreal bevacizumab injection.
Chung EJ; Koh HJ
Korean J Ophthalmol; 2007 Sep; 21(3):185-7. PubMed ID: 17804928
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.
Ladas ID; Kotsolis AI; Papakostas TD; Rouvas AA; Karagiannis DA; Vergados I
Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013
[TBL] [Abstract][Full Text] [Related]
31. Anti-vascular endothelial growth factor monotherapy versus combination treatment with photodynamic therapy for subfoveal choroidal neovascularization secondary to causes other than age-related macular degeneration.
Chen L; Miller JW; Vavvas D; Kim IK
Retina; 2011 Nov; 31(10):2078-83. PubMed ID: 21691258
[TBL] [Abstract][Full Text] [Related]
32. Intravitreal bevacizumab alone versus combined verteporfin photodynamic therapy and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: visual acuity after 1 year of follow-up.
Rudnisky CJ; Liu C; Ng M; Weis E; Tennant MT
Retina; 2010 Apr; 30(4):548-54. PubMed ID: 20386095
[TBL] [Abstract][Full Text] [Related]
33. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy.
Sato T; Kishi S; Matsumoto H; Mukai R
Am J Ophthalmol; 2010 Jun; 149(6):947-954.e1. PubMed ID: 20346441
[TBL] [Abstract][Full Text] [Related]
34. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy.
Wakabayashi T; Gomi F; Sawa M; Tsujikawa M; Nishida K
Br J Ophthalmol; 2012 Mar; 96(3):394-9. PubMed ID: 21719568
[TBL] [Abstract][Full Text] [Related]
35. Photodynamic therapy with or without intravitreal bevacizumab for polypoidal choroidal vasculopathy: two years of follow-up.
Lee YA; Yang CH; Yang CM; Ho TC; Lin CP; Huang JS; Chen MS
Am J Ophthalmol; 2012 Nov; 154(5):872-880.e2. PubMed ID: 22831838
[TBL] [Abstract][Full Text] [Related]
36. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA; Tewari A
Retina; 2006; 26(9):988-93. PubMed ID: 17151484
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of subretinal fluid absorption by optical coherence tomography in circumscribed choroidal hemangioma after photodynamic therapy with Verteporfin.
Soucek P; Cihelková I
Neuro Endocrinol Lett; 2004; 25(1-2):109-14. PubMed ID: 15159693
[TBL] [Abstract][Full Text] [Related]
38. [Combined treatment with photodynamic therapy and intravitreal dexamethasone implant (Ozurdex(®)) for circumscribed choroidal hemangioma].
Bazin L; Gambrelle J
J Fr Ophtalmol; 2012 Dec; 35(10):798-802. PubMed ID: 23040445
[TBL] [Abstract][Full Text] [Related]
39. Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration.
Ladewig MS; Karl SE; Hamelmann V; Helb HM; Scholl HP; Holz FG; Eter N
Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):17-25. PubMed ID: 17701197
[TBL] [Abstract][Full Text] [Related]
40. Intravitreal bevacizumab to treat choroidal neovascularization following photodynamic therapy in central serous choroidopathy.
Montero JA; Ruiz-Moreno JM; Fernandez-Muñoz M
Eur J Ophthalmol; 2011; 21(4):503-5. PubMed ID: 21279982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
